Q&A

Treatment Options For Different Stages Of Prostate Cancer

Have you or a loved one been diagnosed with prostate cancer? Understanding the various treatment options available for different stages of this disease can empower you to make informed decisions.

Navigating the journey through prostate cancer treatment starts with gaining knowledge about how the disease is categorized and what treatments align with each stage. Whether dealing with an early diagnosis or tackling more advanced stages, a spectrum of approaches is designed to manage the disease effectively.

This information provides clarity and hope, showcasing the advancements in medical science that are helping individuals lead healthier lives post-diagnosis. Patients and their families need to engage in open discussions with healthcare professionals to understand each treatment option's potential outcomes and side effects. With this knowledge, making choices that best suit the patient's health, lifestyle, and preferences becomes more guided and less daunting.

This guide will explore the treatments for prostate cancer, from early-stage management to advanced prostate cancer treatment.

Stage I

In the initial stage, cancer is localized and usually grows slowly.

Active Surveillance and Watchful Waiting

This approach is often chosen by those with low-risk, slow-growing prostate cancer. It allows patients to avoid or delay the side effects of more aggressive treatments. Regular monitoring includes PSA blood tests, digital rectal exams, and possibly biopsies to check for any changes in the cancer's behavior.

Radiation Therapy

Radiation therapy can be delivered externally or through radioactive seeds implanted directly into the prostate (brachytherapy). This method can be particularly effective for early-stage prostate cancer and offers a non-surgical option for treatment. Patients typically undergo treatment five days a week for several weeks, requiring minimal recovery time.

Radical Prostatectomy

The decision to proceed with a radical prostatectomy involves considering factors such as the cancer's aggressiveness and the patient's overall health and life expectancy. This procedure can be performed using traditional open surgery, laparoscopically, or robotic technology, which may offer quicker recovery times. Following surgery, patients are closely monitored for signs of cancer recurrence and managed for any potential side effects, such as incontinence or erectile dysfunction.

Ablation Therapy

Ablation therapy is less invasive than surgery and targets only the cancerous cells, preserving as much of the prostate and its functionality as possible. Techniques like cryotherapy freeze the cancer cells, while HIFU uses focused ultrasound waves to heat and eliminate them. These treatments are options for men who wish to minimize the risk of side effects associated with more invasive treatments.

Stage II

Cancer is more significant but remains confined to the prostate.

Active Surveillance

For Stage II prostate cancer, active surveillance involves more frequent monitoring than in Stage I, given the cancer's greater significance. Patients may undergo additional tests, such as MRI scans or targeted biopsies, to closely track the cancer's status without rushing into treatment. This option remains suitable for patients prioritizing quality of life and wanting to delay potential treatment side effects.

Radical Prostatectomy

In Stage II, radical prostatectomy aims to remove cancer that is more significant but still confined to the prostate. The surgery might be more complex due to the cancer's growth, requiring careful removal to ensure clear margins around the prostate. Post-surgery, patients are closely monitored through PSA tests to detect any signs of residual cancer early.

Radiation Therapy, possibly combined with Hormone Therapy

For Stage II prostate cancer, radiation therapy often becomes a more aggressive approach, sometimes paired with hormone therapy to shrink the tumor before radiation. This combination enhances the effectiveness of radiation in targeting and destroying cancer cells. Patients undergoing this treatment might experience more pronounced side effects, necessitating management strategies to maintain quality of life during and after therapy.

Stage III

Cancer has spread beyond the prostate to nearby tissues.

External Radiation plus Hormone Therapy

In Stage III, where cancer has begun to spread, combining external radiation with hormone therapy becomes crucial. Hormone therapy reduces the cancer's size and spread, enhancing the effectiveness of radiation treatment by making cancer cells more susceptible. This approach requires carefully monitoring hormone levels and potential side effects to tailor the treatment to the patient's needs. Patients may experience side effects from both treatments, necessitating a comprehensive management plan. This combination is particularly effective for controlling cancer spread and improving survival rates.

External Radiation plus Brachytherapy and possible Hormone Therapy

This treatment strategy offers a dual approach to radiation, targeting cancer cells from outside and inside the body. By combining external beam radiation with the targeted approach of brachytherapy, and possibly hormone therapy, doctors can attack the cancer more aggressively. The precision of brachytherapy allows for higher doses of radiation directly at the cancer site, minimizing damage to surrounding tissues. Patients undergoing this combination treatment will be closely monitored for response and side effects, adjusting the treatment plan as necessary. This tailored approach maximizes the chances of controlling the cancer's spread.

Radical Prostatectomy, often combined with removal of your pelvic lymph nodes

For Stage III prostate cancer, radical prostatectomy may involve more extensive surgery to remove not just the prostate but also nearby affected tissues and lymph nodes. This procedure is considered when cancer has spread but is thought to be still localized enough for surgery to be effective. The removal of pelvic lymph nodes helps to prevent further spread of the cancer. Post-operative recovery includes managing potential side effects such as urinary incontinence and erectile dysfunction, with rehabilitation and support services playing a crucial role. This aggressive surgical approach is aimed at achieving clear margins around the removed tissues, significantly reducing the risk of cancer recurrence.

Stage IV

Cancer has spread to distant organs and bones.

Hormone Therapy, often combined with Surgery, Radiation, or Chemotherapy

At Stage IV, hormone therapy serves as a cornerstone treatment, aiming to control cancer by reducing testosterone levels, which prostate cancer cells rely on to grow. When combined with surgery, radiation, or chemotherapy, it can significantly slow the progression of metastatic cancer and alleviate symptoms, offering patients better quality of life. This integrated treatment approach is tailored based on the cancer's spread and the patient's health, striving to balance effectiveness with minimizing side effects. Regular monitoring is essential to adjust therapy as the disease evolves. For many patients, this combination therapy provides a means to manage the disease long-term, focusing on symptom relief and maintaining daily functioning.

Surgery to relieve symptoms

In advanced prostate cancer, surgeries are not typically curative but are crucial for symptom management, such as relieving urinary obstruction or bone pain caused by metastases. While not aimed at removing the cancer entirely, these procedures can significantly improve a patient's quality of life. Surgical intervention at this stage requires careful consideration of the patient's health and the potential benefits versus risks. Post-operative care focuses on managing recovery and any side effects, to return the patient to comfort as soon as possible. These interventions underscore the treatment's comforting nature, prioritizing relief and patient well-being.

External Radiation with or without Hormone Therapy

External beam radiation therapy (EBRT) offers targeted relief from pain, especially when cancer has spread to bones. When used alongside hormone therapy, EBRT can also help control the spread of cancer by targeting specific metastatic sites. This approach is often personalized, focusing radiation on areas where cancer causes significant pain or risk of fracture, thus improving mobility and reducing discomfort. Radiation treatment schedules are designed to maximize efficacy while minimizing impact on the patient's daily life. This strategy underscores the goal of maintaining as much normalcy and comfort as possible for the patient.

Chemotherapy

Chemotherapy is a potent option for Stage IV prostate cancer, especially when cancer no longer responds to hormone therapy. It works by circulating throughout the body to kill rapidly dividing cells, including cancer cells, and is particularly useful for aggressive or rapidly spreading cancers. Treatment regimens are carefully planned to manage side effects, such as nausea and fatigue, allowing patients to maintain some activity level and quality of life. Chemotherapy can also be combined with other treatments for a more comprehensive approach to managing advanced prostate cancer. It represents a critical option for controlling disease progression and providing symptom relief.

Bisphosphonate Drugs

Bisphosphonates are specialized medications that strengthen bones and reduce the risk of fractures in patients with cancer that has spread to the bone. These drugs work by inhibiting bone resorption, helping to manage bone pain and prevent skeletal-related events that can significantly impact a patient's mobility and comfort. They are an important part of a multifaceted treatment approach for Stage IV prostate cancer, offering patients a way to maintain bone health and reduce the need for surgical interventions. Regular monitoring and adjustments ensure treatment meets patients' needs without adding undue side effects. Bisphosphonates, thus, play a critical role in preserving the patient's quality of life and independence.

Radiopharmaceuticals

Radiopharmaceuticals offer a targeted approach to treating bone metastases by delivering radiation directly to bone lesions, minimizing damage to surrounding healthy tissue. This treatment can significantly reduce bone pain and help control the spread of cancer in the bones. The precision of radiopharmaceuticals allows for focused treatment, making it a valuable option for patients with advanced prostate cancer affecting the skeleton. These treatments are typically administered in a hospital setting, and patients are monitored closely for any side effects. Radiopharmaceuticals represent a significant advancement in managing bone metastases, providing relief and improved quality of life for many patients.

The vaccine sipuleucel-T (Provenge)

Sipuleucel-T is a form of immunotherapy that stimulates the body's immune system to attack prostate cancer cells. Tailored specifically to each patient, this vaccine is made from the patient's immune cells, which are collected, treated, and reintroduced into the body to target and kill cancer cells. It's particularly beneficial for patients with hormone-resistant prostate cancer, offering a novel treatment avenue when traditional therapies have failed. While not a cure, sipuleucel-T can extend survival and is associated with minimal side effects, making it an important option in the arsenal against advanced prostate cancer. This treatment underscores the ongoing innovation in cancer therapy, providing new hope for patients facing advanced disease.

Palliative Care

Palliative care is an essential component of treatment for Stage IV prostate cancer, focusing on relieving symptoms and improving quality of life. This multidisciplinary approach addresses patients' and their families' physical, emotional, and spiritual needs. Whether it's managing pain, navigating treatment side effects, or providing emotional support, palliative care teams work to ensure patients live as fully and comfortably as possible. This supportive care can be integrated at any stage of treatment, highlighting its role in end-of-life care and comprehensive cancer management. Palliative care emphasizes the patient's well-being, ensuring dignity and comfort during this challenging journey.

Winding Up

Navigating prostate cancer treatment options can seem overwhelming, but understanding the available therapies for each stage can guide you and your healthcare team in choosing the best approach. From active early-stage surveillance to comprehensive treatments for advanced stages, each strategy aims to manage the disease effectively and maintain the quality of life. Always discuss with your healthcare provider to tailor the treatment plan to your needs and preferences.

Hormone Treatment Fights Prostate Cancer

Hormone therapy for prostate cancer has come a long way in the past few decades. Not so long ago, the only hormonal treatment for this disease was drastic: an orchiectomy, the surgical removal of the testicles.

Now we have a number of medications -- available as pills, injections, and implants -- that can give men the benefits of decreasing male hormone levels without irreversible surgery.

"I think hormonal therapy has done wonders for men with prostate cancer," Stuart Holden, MD, Medical Director of the Prostate Cancer Foundation.

Hormone therapy for prostate cancer does have limitations. Right now, it's usually used only in men whose cancer has recurred or spread elsewhere in the body.

But even in cases where removing or killing the cancer isn't possible, hormone therapy can help slow down cancer growth. Though it isn't a cure, hormone therapy for prostate cancer can help men with prostate cancer feel better and add years to their lives.

On average, hormone therapy can stop the advance of cancer for two to three years. However, it varies from case to case. Some men do well on hormone therapy for much longer.

The idea that hormones have an effect on prostate cancer is not new. The scientist Charles Huggins first established this over 60 years ago in work that led to his winning the Nobel Prize. Huggins found that removing one of the main sources of male hormones from the body -- the testicles -- could slow the growth of the disease.

"This procedure worked dramatically," says Holden, who is also director of the Prostate Cancer Center at Cedar Sinai Medical Center in Los Angeles. "Before, these men were confined to bed and wracked with pain. Almost immediately afterwards, they improved."

Huggins found that some types of prostate cancer cells need certain male hormones -- called androgens -- to grow. Androgens are responsible for male sexual characteristics, like facial hair, increased muscle mass, and a deep voice. Testosterone is one kind of androgen. About 90% to 95% of all androgens are made in the testicles, while the rest are made in the adrenal glands located on top of the kidneys.

Hormone therapy for prostate cancer works by either preventing the body from making these androgens or by blocking their effects. Either way, the hormone levels drop, and the cancer's growth slows.

"Testosterone and other hormones are like fertilizer for cancer cells," Holden tells WebMD. "If you take them away, the cancer goes into shock, and some of the cells die."

In 85% to 90% of cases of advanced prostate cancer, hormone therapy can shrink the tumor.

However, hormone therapy for prostate cancer doesn't work forever. The problem is that not all cancer cells need hormones to grow. Over time, these cells that aren't reliant on hormones will spread. If this happens, hormone therapy won't help anymore, and your doctor will need to shift to a different treatment approach.

There are two basic kinds of hormone therapy for prostate cancer. One class of drugs stops the body from making certain hormones. The other allows the body to make these hormones, but prevents them from attaching to the cancer cells. Some doctors start treatment with both drugs in an effort to achieve a total androgen block. This approach goes by several names: combined androgen blockade, complete androgen blockade, or total androgen blockade.

Here's a rundown of the techniques.

Luteinizing hormone-releasing hormone agonists (LHRH agonists.) These are chemicals that stop the production of testosterone in the testicles. Essentially, they provide the benefits of an orchiectomy for men with advanced prostate cancer without surgery. This approach is sometimes called "chemical castration." However, the effects are fully reversible if you stop taking the medication.

Most LHRH agonists are injected every one to four months. Some examples are Lupron, Trelstar, Vantas, and Zoladex. A new drug, Viadur, is an implant placed in the arm just once a year.

Side effects can be significant. They include: loss of sex drive, hot flashes, development of breasts (gynecomastia) or painful breasts, loss of muscle, weight gain, fatigue, and decrease in levels of "good" cholesterol.

Plenaxis is a drug that's similar to LHRH agonists. However, because it can cause serious allergic reactions, it's not used that often.

Anti-androgens. LHRH agonists and orchiectomies only affect the androgens that are made in the testicles. Thus they have no effect on the 5% to 10% of a man's "male" hormones that are made in the adrenal glands. Anti-androgens are designed to affect the hormones made in the adrenal glands. They don't stop the hormones from being made, but they stop them from having an effect on the cancer cells.

The advantage of anti-androgens is that they have fewer side effects than LHRH agonists. Many men prefer them because they are less likely to diminish libido. Side effects include tenderness of the breasts, diarrhea, and nausea. These drugs are also taken as pills each day, which may be more convenient than injections. Examples are Casodex, Eulexin, and Nilandron.

In some cases, starting treatment with an LHRH agonist can cause a "tumor flare," a temporary acceleration of the cancer's growth due to an initial increase in testosterone before the levels drop. This may cause the prostate gland to enlarge, obstructing the bladder and making it difficult to urinate. It's believed that starting with an anti-androgen drug and then switching to an LHRH agonist can help avoid this problem. In patients with bone metastases, this "flare" can lead to significant complications such as bone pain, fractures, and nerve compression.

Strangely, if treatment with an anti-androgen doesn't work, stopping it may actually improve symptoms for a short time. This phenomenon is called "androgen withdrawal," and experts aren't sure why it happens.

Combined Androgen Blockade. This approach combines anti-androgens with LHRH agonists or an orchiectomy. By using both approaches, you can cut off or block the effects of hormones made by both the adrenal glands and the testicles. However, using both treatments can also increase the side effects. An orchiectomy or an LHRH agonist on its own can cause significant side effects like a loss of libido, impotence, and hot flashes. Adding an anti-androgen can cause diarrhea, and less often, nausea, fatigue, and liver problems.

Estrogens. Some synthetic versions of female hormones are used for prostate cancer. In fact, they were one of the early treatments used for the disease. However, because of their serious cardiovascular side effects, they're not used as often anymore. J. Brantley Thrasher, MD, a spokesman for the American Urological Association and chairman of urology at the University of Kansas Medical Center, says they're usually used only after initial hormone treatments have failed. Examples of estrogens are DES (diethylstilbestrol), Premarin, and Estradiol.

Other Drugs.Proscar (finasteride) is another drug that indirectly blocks an androgen that helps prostate cancer cells grow. Depending on the case, doctors sometimes use other anticancer drugs like Nizoral (ketoconazole) and Cytadren (aminoglutethimide.)

Orchiectomy. The surgical removal of the testicles was the earliest form of hormone therapy for prostate cancer. However, the procedure is permanent. As with LHRH agonists, side effects can be significant. They include: Loss of sex drive, hot flashes, development of breasts (gynecomastia) or painful breasts, loss of muscle, weight gain, fatigue, and decrease in levels of "good" cholesterol.

"Since we have other options, orchiectomies really aren't done very much anymore," says Holden.

However, it can be the right choice in certain cases. "Some men might get the procedure because they're tired of getting shots and aren't sexually active anyway," says Thrasher. "Or they may have financial concerns. In the long-run, an orchiectomy is much cheaper than LHRH agonists."

Hormone therapy for prostate cancer can cause bone thinning osteoporosis, which can lead to broken bones. However, treatment with bisphosphonates -- like Aredia, Fosamax, and Zometa -- may help prevent this condition from developing, says Holden.

Unfortunately, understanding the details of hormone therapy for prostate cancer can be difficult. Which drug or combination of drugs works best? In what order should they be tried? Research hasn't answered these questions yet.

"Right now, there's a level of art to figuring out which agents to use," says Durado Brooks, MD, MPH, director of prostate cancer programs at the American Cancer Society. "We don't have clear evidence yet."

LHRH agonists remain the usual first treatment. But in some cases, doctors are trying anti-androgens first. Anti-androgens may be especially appealing to younger men who are still sexually active, since these drugs don't completely shut down sex drive. When anti-androgens stop working -- based on PSA tests -- a person then might shift onto an LHRH agonist.

Other doctors prefer to begin therapy with a combination of two or even three drugs, especially for patients with symptoms or advanced disease, says Holden.

Researchers originally hoped that combined androgen blockade would significantly add to the benefits of LHRH agonists. However, the results, to date, have been mixed. Some studies have shown slightly longer survival with combined androgen blockade, but the results haven't been as dramatic as many experts had hoped. Other studies have shown no benefit. A possible explanation may be the type of anti-androgen used, but further studies are needed to answer this question.

"I think early on, there was hope that it would have a more profound effect," Thrasher tells WebMD.

Brooks agrees. "I think that anti-androgens have made a significant difference in terms of quality of life for men with advanced prostate cancer," says Brooks. "However, we haven't really seen proof that they let people live longer" when combined with LHRH agonists.

Experts debate how early treatment with hormone therapy should be started. Some argue that the benefits of hormone therapy for prostate cancer should be offered to men earlier in the course of the disease. Others assert that there's little evidence that getting treatment early is better than getting it later.

"Unfortunately, there are still some doctors who are offering hormonal therapy earlier in the course of the disease than is commonly recommended," Brooks says. Given that the side effects can be serious, Brooks argues that starting treatment with hormone therapy so early may not be a good idea.

However, Holden argues that early treatment may be helpful. "I think one of the reasons that the death rate from prostate cancer is going down is that we're using hormone therapy early," he tells WebMD. "We haven't proved that early treatment improves overall survival yet, but I think we will."

Researchers are also looking at "intermittent therapy," starting and stopping hormone treatment for months at a time. The big advantage is that men could go off therapy temporarily and thus be free of the side effects. Early study results have been promising.

Hormone therapy for prostate cancer is also being tested in combination with other therapies, like radiation and chemotherapy. One recent study looked at men with locally advanced prostate cancer - cancer that has spread outside the prostate, but not yet into other parts of the body. Researchers found that adding just six months of hormone therapy to radiation allowed the men to live longer. Researchers are also studying the effects of hormone therapy earlier in treatment, for instance right after or even before surgery.

Some experts aren't sure how much further we can improve hormone therapy for prostate cancer.

"I'm not saying that we've reached the end of what we can do with hormonal therapy," Thrasher tells WebMD, "but there are only so many ways to shut down the hormonal effects. The cancer will still eventually escape."

Brooks argues that, overall, prostate cancer is only moderately affected by hormones. "You can only do so much manipulating the levels of hormones," says Brooks. "We have to find better ways to fight the basis of the cancer cells."

Thrasher and Brooks have more hope that the next breakthroughs will come with different approaches, like chemotherapy or vaccines.

But Holden remains optimistic about the future of hormone therapy for prostate cancer.

"Cancer cells eventually figure out how to survive, how to overcome a specific hormone therapy," he says. "But if we have enough types of drugs and can keep changing the hormone therapy, we might be able to keep the cancer cells in a state of confusion. We could change therapies before they have a chance to adapt."

"It's like an endless chess game," he says. "You may not ever win, but you might be able to prolong the game indefinitely. I think that hormone therapy still has a lot of promise. We just need to develop better anti-androgens, and more varieties of them."

While experts debate the best way to use hormone therapy for prostate cancer, they do agree on the strides we've made in treating this disease. Improved detection and treatment -- like hormone therapy -- have really changed the picture.

"Prostate cancer is really a different disease than it was 15 years ago," says Thrasher. "Men who have recurrent prostate cancer are living so much longer than they used to."

Published May 2005.

Prostate Cancer News

June 5, 2024 — As prostate cancer progresses, it becomes increasingly aggressive and can metastasize. In this form, the tumor is difficult to treat, which is reflected in high mortality rates: Worldwide, the ...

Jan. 23, 2024 — Combining testosterone-blocking drugs in patients with prostate cancer relapse prevents the spread of cancer better than treatment with a single drug, a multi-institution, Phase 3 clinical trial has ...

Nov. 9, 2023 — A globe-spanning scientific team has compiled the most comprehensive list of genetic variants associated with prostate cancer risk -- 451 in all -- through a whole-genome analysis that ranks as the ...

Oct. 18, 2023 — Investigators have identified two promising new treatment options for men with recurrent prostate cancer -- both of which helped patients live longer without their disease progressing than the ...

Aug. 22, 2023 — Using MRI as a screening test alongside PSA density allowed detection of cancers that would have been missed by the blood test alone, according to new ...

Aug. 15, 2023 — Researchers demonstrate how mathematical modeling combined with dynamic biomarkers can be used to characterize metastatic disease and identify appropriate therapeutic approaches to improve patient ...

Aug. 14, 2023 — A study uncovers a new mechanism to explain why some prostate tumors switch from a common, treatable form to a more rare and aggressive form of prostate ...

Aug. 14, 2023 — Patients with localized prostate cancer have a good chance of survival, but mortality rates among those with advanced, metastatic forms of the condition remain high. Until now, the precise mechanism ...

July 19, 2023 — Three new biomarkers for prostate cancer have been identified to help pinpoint potentially aggressive cases of the disease, which kills 300,000 men each ...

July 12, 2023 — Prostate cancer is a leading cause of death among American men, and it's resistant to one of the most powerful chemotherapy medications -- cisplatin. Now, researchers have developed the first ...

Apr. 10, 2023 — A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 ...

Mar. 16, 2023 — The combination of two oral medications has shown positive results in people with prostate cancer, whose disease has spread to other parts of the body. Compared with XTANDI plus placebo, the ...

Mar. 9, 2023 — New research shows that men who stick to a predominantly Mediterranean diet are less likely to be diagnosed with prostate cancer. This diet also improves their chances of recovery if they have PC and ...

Mar. 8, 2023 — The nitrate ingested over the course of a person's adult lifetime through the consumption of tap water and bottled water could be a risk factor for prostate cancer, particularly in the case of ...

Feb. 7, 2023 — Researchers have helped develop a new blood test to detect prostate cancer with greater accuracy than current methods. New research shows that the Prostate Screening EpiSwitch (PSE) blood test is ...

Jan. 23, 2023 — Researchers discover a potential therapeutic avenue via neuronal endocrine receptors that could be helpful in battling an aggressive form of prostate ...

Jan. 12, 2023 — For men who undergo radiotherapy for localized prostate cancer, the precise targeting capabilities of MRI guidance resulted in fewer toxicities and better quality of life according to new ...

Dec. 14, 2022 — A single bout of exercise has been shown to elevate anti-cancer proteins called myokines in people with advanced prostate cancer, to levels which can significantly suppress tumour ...

Dec. 13, 2022 — Researchers have characterised prostate cancer cell dynamics at a single-cell resolution across the timespan of the disease -- from its beginning to the point of androgen independence, where the ...

Dec. 9, 2022 — Scientists have created a comprehensive tool for predicting an individual's risk of developing prostate cancer, which they say could help ensure that those men at greatest risk will receive the ...

---